Baxter International and Water Street Healthcare have received approval from the US Food and Drug Administration (FDA) for Cefazolin Injection in Galaxy container (2g/100ml).
Cefazolin Injection is a cephalosporin antibacterial suggested for preoperative prophylaxis treatment.
Baxter hospital products business president Brik Eyre said: "The availability of Cefazolin 2g in an efficient, ready-to-use, flexible, premix container that can improve pharmacy efficiency will provide additional supply options of an important antibiotic.
"Baxter’s innovative development partnership with Water Street allows us to accelerate product development and offers healthcare providers additional options for critical care medications produced with our proprietary manufacturing capabilities and in our container technology."
Cefazolin Injection 2gm is the first of nine molecules Baxter developed under a partnership with Celerity Pharmaceuticals, a company of Water Street.
See Also:
The firm plans to introduce Cefazolin 2g frozen premix in its Galaxy container in the US during the fourth quarter of this year.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataCefazolin Injection must be used only to prevent infections that are proven or strongly suspected to be caused by bacteria, in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of the treatment.
According to the firm, clostridium difficile associated diarrhoea (CDAD) has been reported with Cefazolin Injection and may range in severity from mild diarrhoea to fatal colitis.
Baxter offers a wide range of essential renal and hospital products, including home, acute and in-centre dialysis, infusion systems and devices, parenteral nutrition, and biosurgery products and anaesthetics.